Enfusion, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Oleg Movchan
- Full Time Employees
- 1,143
- Sector
- Technology
- Industry
- Software - Application
- Address
- 125 South Clark Street Chicago IL United States of America 60603
- IPO Date
- Oct 21, 2021
- CIK
- 0001868912
- Website
- enfusion.com
- Similar Companies
- Business
- Enfusion, now operating as a Clearwater Analytics company, delivers comprehensive software-as-a-service solutions to the global investment management sector, spanning the United States, Europe, the Middle East, Africa, and the Asia Pacific region. The firm’s integrated, cloud-native platform is engineered to unify front, middle, and back-office operations, providing investment managers with real-time, data-driven intelligence. Central to its offerings is the Portfolio Management System, which generates an immediate investment book of record, offering valuation and risk assessment tools for chief investment officers and portfolio managers to analyze aggregated or granular portfolio data. Additionally, the platform features an Order and Execution Management System, enabling portfolio managers, traders, and compliance personnel to digitally transmit trade orders across diverse asset classes, manage transactions efficiently, and systematically enforce trading rules and internal compliance. Enfusion also provides an Accounting/General Ledger System, establishing a live accounting book of record that automates the posting of general ledger entries for all cash and securities activities, benefiting chief financial officers, chief operating officers, accountants, and operations teams. Complementing this is the Enfusion Analytics System, empowering CIOs, portfolio managers, traders, and analysts to examine portfolios across various time horizons and produce automated, customized visual reports for both internal and external stakeholders. The company further extends its capabilities through technology-driven and managed services. Originally founded in 1997, Enfusion, Inc. completed its acquisition by Clearwater Analytics in April 2025, a move valued at approximately $1.5 billion, creating a unified front-to-back platform for the investment management industry. It maintains its headquarters in Chicago, Illinois.
Clearwater Analytics: Q3 Figures Show Enfusion Acquisition Brings Meaningful Growth
Clearwater Analytics: 3 Acquisitions That Make This A Strong Buy
Clearwater Analytics Finalizes Acquisition of Enfusion
Clearwater Analytics and Enfusion Announce Preliminary Results of Election by Enfusion Shareholders Regarding Form of Merger Consideration
Clearwater Analytics and Enfusion Announce Election Deadline for Enfusion Shareholders to Elect Form of Merger Consideration
ENFUSION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enfusion, Inc. - ENFN
Enfusion, Inc. (ENFN) Lags Q4 Earnings and Revenue Estimates
Enfusion Announces Fourth Quarter and Full Year 2024 Results
Clearwater Analytics and Enfusion Announce Expiration of Hart-Scott-Rodino Act Waiting Period For Proposed Acquisition of Enfusion
ENFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enfusion, Inc. Is Fair to Shareholders
Clearwater Analytics' Enfusion Infusion Offers Compelling Value Proposition, Analyst Upgrades Stock
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Is Investigating Enfusion, Inc. (ENFN) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Encourages Enfusion, Inc. (ENFN) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Enfusion, Inc. (ENFN) and Encourages Investors to Learn More About the Investigation
Enfusion, Inc. (ENFN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Enfusion, Inc. For Securities Fraud
Enfusion, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Enfusion, Inc. (ENFN) And Encourages Stockholders to Reach Out